LitAlert ~~ GeneLit.com

    • Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer.
    • [No author given]
    • FORCE. 2020 Jul 7.

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • Lifestyle Choices May Reduce Breast Cancer Risk Regardless of Genetics.
    • Otto MA.
    • Medscape. 2020 Jul 7.

    Original research:

    Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort.

    Research news: Lifestyle choices may reduce breast cancer risk regardless of genetics. (MDedge | Hematology & Oncology)

    • Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
    • Desai NV, Tung NM.
    • Breast J. 2020 Jul 6. doi: 10.1111/tbj.13972. Online ahead of print.
    • Review
    • Complex Characterization of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center.
    • Bozsik A, Pócza T, Papp J, Vaszkó T, Butz H, Patócs A, Oláh E.
    • Int J Mol Sci. 2020 Jun 30;21(13):E4650. doi: 10.3390/ijms21134650.
    • Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
    • McAllister F, Maitra A, Burton M, McGuire M..
    • Medscape. 2020 Jun 25.